We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+32.51%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$427M
AUM Growth
+$52.8M
Cap. Flow
-$11.7M
Cap. Flow %
-2.75%
Top 10 Hldgs %
60.67%
Holding
34
New
2
Increased
10
Reduced
13
Closed
2
Avg Time Held
1.4 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
1.1 years

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$581M
$77.9M 18.23%
7,648,268
– –
2021 Q1
11 quarters
IOVA icon
2
Iovance Biotherapeutics
IOVA
$3.41B
$26.7M 6.26%
3,289,470
+2,073
+0.1% +$10.8K
2022 Q2
6 quarters
OLMA icon
3
Olema Oncology
OLMA
$615M
$26.1M 6.1%
1,857,136
-545
-0% -$7.32K
2023 Q2
2 quarters
GERN icon
4
Geron
GERN
$615M
$22.6M 5.29%
10,715,620
+3,139
+0% +$6.1K
2021 Q3
9 quarters
ITOS icon
5
DELISTED
iTeos Therapeutics
ITOS
$19.1M 4.47%
1,745,943
– –
2020 Q3
13 quarters
ALXO icon
6
ALX Oncology
ALXO
$140M
$18.8M 4.41%
+1,264,759
New +$12M
2023 Q4
0 quarters
MLTX icon
7
MoonLake Immunotherapeutics
MLTX
$937M
$17.8M 4.16%
294,576
+386
+0.1% +$19.9K
2023 Q2
2 quarters
CRNX icon
8
DELISTED
Crinetics Pharmaceuticals
CRNX
$17M 3.98%
478,234
-819
-0.2% -$25.1K
2021 Q3
9 quarters
KRTX icon
9
DELISTED
Karuna Therapeutics
KRTX
$16.9M 3.95%
53,279
+69
+0.1% +$13.4K
2023 Q2
2 quarters
INSM icon
10
Insmed
INSM
$31.1B
$16.4M 3.83%
528,150
+692
+0.1% +$17.9K
2022 Q4
4 quarters
CBAY icon
11
DELISTED
Cymabay Therapeutics
CBAY
$14.4M 3.38%
611,181
+411
+0.1% +$7.32K
2023 Q3
1 quarter
RPTX icon
12
DELISTED
Repare Therapeutics
RPTX
$12M 2.8%
1,639,849
– –
2020 Q2
14 quarters
NTLA icon
13
Intellia Therapeutics
NTLA
$1.31B
$11.7M 2.73%
382,598
-162,041
-30% -$4.66M
2021 Q3
9 quarters
FOLD icon
14
DELISTED
Amicus Therapeutics
FOLD
$10.2M 2.38%
715,883
-256
-0% -$2.91K
2021 Q3
9 quarters
RGNX icon
15
Regenxbio
RGNX
$471M
$9.9M 2.31%
549,078
-107,640
-16% -$1.9M
2022 Q3
5 quarters
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$9.22B
$9.47M 2.21%
40,910
+51
+0.1% +$8.92K
2022 Q2
6 quarters
GPCR icon
17
Structure Therapeutics
GPCR
$1.23B
$9.4M 2.2%
230,696
-65
-0% -$3.72K
2023 Q3
1 quarter
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$9.39M 2.2%
664,986
+762
+0.1% +$8.95K
2023 Q2
2 quarters
MORF icon
19
DELISTED
Morphic Holding
MORF
$9.35M 2.19%
323,742
+123,742
+62% +$2.95M
2023 Q3
1 quarter
HOWL icon
20
Werewolf Therapeutics
HOWL
$46.7M
$9.22M 2.16%
2,388,011
– –
2021 Q2
10 quarters
RLAY icon
21
Relay Therapeutics
RLAY
$3.54B
$9.16M 2.14%
832,017
-520,116
-38% -$4.39M
2023 Q1
3 quarters
XERS icon
22
Xeris Biopharma Holdings
XERS
$3.01B
$9.04M 2.12%
3,847,232
-140,735
-4% -$260K
2023 Q2
2 quarters
VERV icon
23
DELISTED
Verve Therapeutics
VERV
$8.9M 2.08%
638,163
-219,777
-26% -$2.72M
2022 Q3
5 quarters
RVMD icon
24
Revolution Medicines
RVMD
$34.7B
$7.84M 1.83%
273,408
– –
2021 Q3
9 quarters
AXSM icon
25
Axsome Therapeutics
AXSM
$7.06B
$7.43M 1.74%
93,387
-199
-0.2% -$13.3K
2022 Q4
4 quarters

Similar funds

MPM BioImpact's Q4 2023 Portfolio in Review

As of Q4 2023, MPM BioImpact held 34 positions worth $427M, up 14% from $375M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

MPM BioImpact's Q4 2023 filing shows 2 new, 10 increased, 13 reduced and 2 closed positions. Its largest new stake was ALX Oncology: 1,264,759 shares worth $18.8M. The largest sale was KalVista Pharmaceuticals, an estimated $5.57M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q4 2023 buy was ALX Oncology: 1,264,759 shares worth $18.8M.
  • MPM BioImpact added most to Morphic Holding in Q4 2023, an estimated $2.95M increase.
  • MPM BioImpact's biggest Q4 2023 reduction was Intellia Therapeutics, cutting an estimated $4.66M.
  • MPM BioImpact fully exited KalVista Pharmaceuticals in Q4 2023, selling an estimated $5.57M.
  • MPM BioImpact's ten largest holdings make up 61% of its $427M portfolio in Q4 2023.
  • MPM BioImpact opened 2 new positions and closed 2 in Q4 2023.
  • MPM BioImpact's portfolio value rose 14% quarter-over-quarter to $427M.

Based on MPM BioImpact's 13F filing for Q4 2023, filed 13 Feb 2024.